In recent years, there has been a dramatic rise in available disease-modifying therapies (DMTs) approved for the treatment of multiple sclerosis (MS), including the introduction of oral medications such as dimethyl fumarate (DMF) and fingolimod (FTY). DMF (240 mg, 1 tablet twice daily) was approved by the US Food and Drug Administration (FDA) and European Medicines Agency in 2013.^[@R1],[@R2]^ FTY (0.5 mg, 1 tablet once daily), a sphingosphine-1 phosphate receptor modulator, was approved by the FDA in 2010 and European Medicines Agency in 2011.^[@R3][@R4][@R5]^

Phase 3 randomized controlled trials (RCTs) showed similar reductions in the annualized relapse rate (ARR) of 44%--53% for DMF and 48%--54% for FTY, when compared against placebo.^[@R1],[@R2],[@R4],[@R5]^ However, DMF and FTY tolerability profiles had prominent differences. By 24 months, 12%--16% and 5.6%--8.5% of DMF and FTY patients discontinued treatment in the RCTs due to adverse events (AEs), respectively.^[@R1],[@R2],[@R4],[@R5]^ Common DMF AEs included flushing and gastrointestinal issues, such as nausea, diarrhea, and vomiting, which were most prominent during the first 1--2 months of treatment.^[@R1],[@R2]^ Common FTY AEs included mild to moderate upper respiratory tract infections, headaches, and back pain. Rare but more important risks included lymphopenia and cardiovascular AEs, fatal herpesvirus infections, and macular edema.^[@R5],[@R6]^ Rare cases of progressive multifocal leukoencephalopathy have been reported for both DMF and FTY.^[@R7][@R8][@R10]^

No RCT directly comparing DMF and FTY has been conducted. Previous single-site, observational studies in a real-world setting demonstrated similar effectiveness outcomes and an increased likelihood of discontinuing DMF by 24 months compared to FTY.^[@R11][@R12][@R13]^ Two-site studies may allow investigators to ascertain external validity of previously examined treatment effect differences. Therefore, we aimed to address this knowledge gap by comparing discontinuation and effectiveness of DMF and FTY over 24 months in patients treated at 2 large academic MS centers. Propensity score (PS) analysis was used to reduce confounding and certain biases.^[@R14]^

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

This study was approved by institutional review boards at the Cleveland Clinic and University of Colorado. Informed consent was waived for this study.

Patient population {#s1-2}
------------------

We conducted a retrospective observational study of patients with MS followed at the Cleveland Clinic Mellen Center or the Rocky Mountain MS Center at the University of Colorado (RMMSC at CU) treated either with DMF or FTY with available 24-month follow-up data. Patients treated at Cleveland Clinic were selected from those starting DMF or FTY within 1 year of respective FDA approval. Patients treated at RMMSC at CU were selected from those starting DMF or FTY prior to October 2013. Each center included a sample size reflective of individual treatment arms in the respective phase 3 trials.^[@R1],[@R2],[@R4],[@R5]^ Relapsing and progressive MS were included in this study to demonstrate the real-world experience of DMT use. Subgroup analyses were also conducted for patients with relapsing-remitting MS (RRMS) and for groups stratified by age (\<40 years old/≥40 years old), sex (male/female), drug line use (first-line/non-first-line), presence of gadolinium-enhancing (GdE) lesions on baseline brain MRI (present/not present), baseline MRI lesion burden (mild/moderate to severe), and patients who switched directly from natalizumab to either DMF or FTY.

Data collection {#s1-3}
---------------

Patients who met inclusion criteria were identified, and a retrospective chart review of the electronic medical record (EMR) was completed at each center to collect baseline and outcomes data 24 months after DMT initiation. Baseline covariates were collected from 12 months prior to respective treatment exposure.

Follow-up postbaseline (e.g., MRI frequency/protocols and visits) was similar between groups. Clinical relapses, defined as new or worsening MS symptoms lasting greater than 24 hours without a coexistent illness or fever, were verified by the treating clinicians and documented in the EMR. Number of new T2 brain lesions and semiquantitative assessment of overall lesion burden were determined manually by C.M.H. at Cleveland Clinic, B.V. at RMMSC at CU, and neuroradiologists at each institution.

Cleveland Clinic data were stored using Redcap software and stored on a secure Cleveland Clinic server. RMMSC at CU data were encrypted and stored on a secure server using Excel. The data from each center were de-identified and merged into a single Excel database.

Outcome measures {#s1-4}
----------------

The primary outcome was the proportion of patients who discontinued DMF or FTY by 24 months. Secondary outcomes included reason for discontinuation (categorized as intolerance or disease activity), time to discontinuation, proportion with clinical relapses, proportion with brain MRI GdE lesions, proportion with new brain MRI T2 lesions, proportion with brain MRI activity (defined as new T2 or GdE lesions), and proportion with absence of disease activity (defined as freedom from clinical relapses and MRI activity). All effectiveness outcomes, including clinical relapse and MRI activity, were on-treatment measures.

Statistical analysis {#s1-5}
--------------------

De-identified data were imported into R version 3.4.2 for analysis.^[@R15]^ We used the same approach as in our previous 12- and 24-month studies to account for missingness patterns in the PS.^[@R12],[@R16]^ Two-tailed *p* values \<0.05 were considered statistically significant. Differences between groups for unadjusted estimates were assessed using *t* tests for continuous data, χ^2^ tests for categorical data, and Cox proportional hazards models and Kaplan-Meier survival analyses for survival outcomes.^[@R12],[@R16]^ Adjusted analyses were conducted using PS methods.

The PS model was built as a logistic regression to calculate the likelihood of initiating DMF, as compared to FTY, using preselected demographics and baseline clinical and MRI characteristics (figure e-1, [links.lww.com/CPJ/A33](http://links.lww.com/CPJ/A33)). A PS was derived for each patient and used in average treatment effect on the treated (ATT) weighting to identify patients in the DMF and FTY groups who were comparable at baseline except for treatment. All covariates included were missing in fewer than 10% of patients.

Similar to our previous single-center 24-month study, we compared the standardized differences in covariates before and after propensity adjustment to determine the strength of our weighting method.^[@R12]^ Excellent covariate balance was defined as an absolute standardized difference \<10% on the covariate means across the 2 DMTs. Treatment groups were compared with conditional logistic regression to obtain odds ratio (OR) estimates for binary outcomes after ATT weighting. Survival data were estimated by stratified Cox regression and Kaplan-Meier survival curves. ORs and hazards ratios (HRs) refer to patients treated with DMF compared to those treated with FTY.^[@R12]^

Data Availability {#s1-6}
-----------------

Anonymized data can be shared at the request of qualified investigators for purposes of replicating procedures and results.

Results {#s2}
=======

Baseline characteristics {#s2-1}
------------------------

[Figure 1](#F1){ref-type="fig"} shows the overall study flow. A total of 1,272 patients were included. Baseline characteristics are presented in [table 1](#T1){ref-type="table"}. Differences were observed in the following covariates: age, race, type of MS, last DMT prior to DMF or FTY, and baseline MRI lesion burden (see [table 1](#T1){ref-type="table"} for details).

![Study flow diagram\
Discontinuations due to other include pregnancy, insurance issues, patient preference, and loss to follow-up. DMF = dimethyl fumarate; FTY = fingolimod; RMMSC at CU = Rocky Mountain Multiple Sclerosis Center at the University of Colorado.](NEURCLINPRACT2018026377FF1){#F1}

###### 

Baseline characteristics of study population

![](NEURCLINPRACT2018026377TT1)

Propensity model {#s2-2}
----------------

The propensity model was created using covariates included in [table 1](#T1){ref-type="table"}. Missing data among covariates in the PS model did not meaningfully change overall covariate balance after PS analysis. Prior to propensity adjustment, the treatment groups were not well-balanced (absolute value of the standardized difference of the linear PS, comparing DMF to FTY = 51.8%). We effectively achieved well-balanced groups through ATT weighting with no covariates having an absolute standardized difference greater than 10% (figure e-1, [links.lww.com/CPJ/A33](http://links.lww.com/CPJ/A33)). PS weighting also produced a comparable linear PS distribution with a standardized difference of 4.3%, well within the 50% standard proposed by Rubin.^[@R17]^

Outcomes for overall population {#s2-3}
-------------------------------

[Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} present a summary of unadjusted and propensity-adjusted outcome estimates using ATT weighting. Figure e-2 ([links.lww.com/CPJ/A33](http://links.lww.com/CPJ/A33)) demonstrates Kaplan-Meier plots for DMT discontinuation for any reason, due to intolerability, and due to MRI activity through 24 months. Discontinuation was more common in DMF patients (n = 326, 44.2%) compared to FTY patients (n = 186, 34.8%) over 24 months (OR 1.55, 95% confidence interval \[CI\] 1.21--1.99, *p* \< 0.001) and occurred earlier in DMF patients (HR 1.48, 95% CI 1.25--1.74, *p* \< 0.001), as confirmed via Kaplan-Meier survival curves (figure e-2a). Intolerability was the most common reason for discontinuation in both groups (DMF n = 183, 24.8%; FTY n = 86, 16.1%), though DMF patients were more likely to discontinue therapy due to intolerability compared to FTY patients (OR 1.65, 95% CI 1.21--2.25, *p* = 0.002). The primary reason for discontinuation due to intolerability was gastrointestinal side effects with DMF (57.9%) and headaches with FTY (14.0%). There was no difference between DMF and FTY for discontinuation due to disease activity (DMF n = 74, 10.0%; FTY n = 61, 11.4%; OR 1.03, 95% CI 0.69--1.53, *p* = 0.892).

###### 

Unadjusted outcomes at 24-month follow-up
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###### 

Unadjusted and adjusted endpoints of DMF compared to FTY at 24 months
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PS weighting analyses demonstrated no differences between DMF and FTY for any effectiveness outcome, including proportion with clinical relapses (OR 1.27, 95% CI 0.90--1.80, *p* = 0.174), brain MRI activity (OR 1.08, 95% CI 0.80--1.46, *p* = 0.595), new T2 lesions (OR 1.13, 95% CI 0.83--1.55, *p* = 0.433), and new GdE lesions (OR 1.42, 95% CI 0.92--2.20, *p* = 0.114). By 24 months, 325 DMF patients (61.2%) demonstrated absence of disease activity vs 282 FTY patients (63.4%) (OR 0.84, 95% CI 0.70--1.27, *p* = 0.268).

Subgroup analyses {#s2-4}
-----------------

[Figure 2](#F2){ref-type="fig"} and tables e-1 through e-14 ([links.lww.com/CPJ/A34](http://links.lww.com/CPJ/A34)) present a summary of unadjusted outcome estimates and propensity-adjusted outcome estimates using ATT weighting for patients with RRMS and groups stratified by age, sex, drug line use, presence of GdE lesions at baseline, baseline MRI lesion burden, and patients who switched from natalizumab. Patients with RRMS demonstrated results consistent with the overall group, with the exception of DMF demonstrating increased odds of GdE lesions compared to FTY (OR 1.62, 95% CI 1.02--2.58). After PS adjustment, older patients were more likely to discontinue DMF compared to FTY (OR 1.43, 95% CI 1.04--1.95), whereas younger patients were equally likely to discontinue either therapy (OR 1.48, 95% CI 0.95--2.31). Natalizumab switchers were equally likely to remain on FTY or DMF (OR 1.41, 95% CI 0.79--2.54). Women had higher likelihood of DMF discontinuation due to intolerability compared to FTY-treated patients (OR 2.17, 95% CI 1.50--3.13), which was not seen in men. Men treated with DMF vs FTY had higher likelihood of GdE lesions (OR 2.78, 95% CI 1.32--5.82), though relapse rates and new T2 lesions were comparable. DMF first-line users had a higher likelihood of clinical relapses (OR 1.56, 95% CI 1.08--3.57) compared to FTY first-line users. No other subgroup analyses demonstrated differences in effectiveness outcomes.

![Forest plots for subgroup analyses\
\*Free of clinical relapses, GdE lesions, and new T2 lesions calculated from those with complete data available. (A) Forest plot demonstrates discontinuation ≤24-month follow-up for subgroups. (B) Forest plot demonstrates absence of disease activity at 24-month follow-up for subgroups. DMF = dimethyl fumarate; FTY = fingolimod; OR = odds ratio; RRMS = relapsing-remitting multiple sclerosis; GdE = gadolinium-enhancing lesion; NTZ natalizumab; = N/S = nonsignificant.](NEURCLINPRACT2018026377FF2){#F2}

Discussion {#s3}
==========

We investigated the discontinuation and comparative effectiveness of DMF and FTY over 24 months in a large population from 2 academic MS centers with a sample size exceeding that in most MS phase 3 RCTs. Consistent with our previous 24-month single-center studies, DMF demonstrated higher odds of discontinuation compared to FTY.^[@R11],[@R12]^ Further, we observed a greater proportion of discontinuations for both DMF and FTY than what was observed in respective phase 3 RCTs (DMF: 44.2% vs 30%--31% in phase 3 RCTs; FTY: 34.8% vs 18.8%--32% in phase 3 RCTs).^[@R1],[@R2],[@R4],[@R5]^ This difference highlights the importance of conducting observational studies, for patients in a real-world setting may differ in motivation to remain on treatment compared to those in a highly regimented RCT. For instance, in clinical practice we anticipate that the provider and patient may be less inclined to continue a DMT with AEs or disease activity when other treatment options are available. In addition, our study had broader inclusion criteria, allowing us to investigate effects more representative of the general population treated in clinical practice, including use in progressive disease and older patients.

Based on our results, intolerability appeared to be the driving force for the observed difference in discontinuation between DMF and FTY. Discontinuation due to intolerability occurred earlier with DMF during the first 6 months of treatment and then began to decrease in rate, appearing more similar to FTY, which is reassuring for DMT persistence in longer-term disease management. This finding was consistent with that of clinical trials that demonstrated gastrointestinal AEs to be common in the first 60 days of DMF treatment.^[@R1],[@R2]^ Discontinuation due to disease activity was comparable for DMF and FTY in the overall group.

Similar to our single-center 24-month investigations, DMF and FTY demonstrated comparable clinical and radiologic effectiveness, with low proportions of patients who experienced a clinical relapse and MRI activity. These results were also consistent with previous PS-adjusted analyses indirectly comparing DMF and FTY patients from the pivotal phase 3 RCTs and directly comparing DMF and FTY in a large claims database analysis. Both investigations found no differences in efficacy via ARR.^[@R18],[@R19]^ In addition, we observed a lower proportion of patients who experienced a relapse over 2 years while on treatment in the entire group (DMF = 15.1%, FTY = 13.1%) and RRMS subgroup (DMF = 16.3%, FTY = 13.5%) compared to phase 3 RCTs (DMF = 27%--29%, FTY = 28.5%--29.6%), which is reassuring for confirming treatment effectiveness in real-world practice. The observed difference was likely, in part, reflective of the inclusion of older patients in our study with both active and inactive baseline disease activity, whereas RCTs were restricted to younger patients with recent disease activity.^[@R20],[@R21]^

As the number of highly effective treatments for MS grows, the treat-to-target outcome measure of no evidence of disease activity (NEDA), defined as no relapses, disability progression, or MRI activity (new or enlarging T2 lesions or GdE lesions), is increasingly utilized in MS studies.^[@R22]^ In our investigation, we measured absence of disease activity (clinical relapses and MRI activity) to explore freedom from inflammatory disease.^[@R12]^ Due to the retrospective nature of our study, measures of disability were not available consistently and, therefore, were not included in our definition of absence of disease activity outcome. We found no differences between DMF and FTY. This finding is contradictory to an indirect comparison model of phase 3 RCT data, conducted by Nixon et al.,^[@R23]^ which demonstrated a reduced probability of achieving NEDA in DMF patients compared to those treated with FTY. We suspect that the reasons for these differences were multifactorial: different study populations (real-world observational data vs clinical trial data), types of comparisons (direct vs indirect), and different NEDA/absence of disease activity definitions.^[@R23]^

Previous analyses of phase 3 RCT studies demonstrated consistent efficacy for DMF and FTY compared to placebo over a broad range of patient subgroups.^[@R24][@R25][@R26]^ The majority of our DMF vs FTY subgroup analyses demonstrated comparable effectiveness across multiple clinical and radiographic outcomes, similar to our overall group. Exceptions were patients with RRMS, first-line users, and men after PS adjustment. For RMMS, DMF patients demonstrated greater likelihood of new GdE lesions than FTY patients; however, the magnitude of this difference was likely small, as the overall MRI activity and absence of disease activity endpoints were comparable. DMF first-line users demonstrated a greater likelihood of clinical relapses and lower likelihood of absence of disease activity, suggestive of reduced effectiveness in this group. In addition, the DMF male population demonstrated a greater likelihood of new GdE lesions. This finding among men observed in our study was consistent with previous literature investigating DMF compared to placebo. In a phase 2 RCT for DMF, the reduction in the number of new GdE lesions remained significant in all subgroups except for male patients.^[@R27]^ However, this study investigated DMF at 240 mg 3 times daily rather than the approved twice daily formulation, and insignificant results were attributed to small sample sizes and low disease activity at baseline in men.^[@R27]^ In addition, while our data suggested improved effectiveness in first-line users and men treated with FTY based on a few endpoints, these were limited either by small sample sizes or wide CIs and warrant cautious interpretation.

Interestingly, women discontinued DMF more due to intolerability, which was not seen in men. Previous research demonstrated that female patients were more likely to discontinue DMTs,^[@R28]^ which was supported by our unadjusted results in table e-3 ([links.lww.com/CPJ/A34](http://links.lww.com/CPJ/A34)), demonstrating slightly higher proportions of DMT discontinuation in women compared to men. The observed sex differences in DMT discontinuation may be clinically relevant and warrant further investigation.

Although our PS model improved baseline covariate balance, we recognize the possibility for residual and hidden biases that available covariates do not address. However, our PS methods included important baseline characteristics that are incorporated into the shared decision-making model of choosing a DMT in clinical practice. The inclusion of subgroup PS analyses provided additional information on distinct groups that allowed us to confirm treatment effects, including analysis of a separate RRMS subgroup to ascertain treatment effects in a population of patients similar to those in phase 3 RCTs. Furthermore, this study included data from 2 academic MS centers, allowing us to ascertain external validity of previously examined treatment effect differences.

Our study has other limitations, owing to the assumptions inherent in observational studies, even after the application of PS adjustment. Certain challenges, such as balancing patients treated with natalizumab vs those with early disease, are inherent aspects of observational studies regardless of PS analysis. As such, separate subgroup analyses comparing natalizumab switchers were conducted to account for this limitation. Further, differences in counseling practices between providers and DMT administration in patients with lower baseline disease activity who may have lower tolerance for AEs may have contributed to the differences in discontinuation between DMF and FTY, which cannot be accounted for through PS adjustment. While our retrospective chart review design allowed for the inclusion of clinical and MRI data not available through other sources, such as claims data, we were limited by previous clinician-reported and missing data that are inherent aspects of observational studies. As a result, we were unable to clarify inconsistencies in the patient chart if they arose. Particularly when inconsistencies were observed, the investigators used data from the chart note closest in date to the event of interest in order to reduce recall bias. In addition, while inclusion of older and progressive patients is representative of the general population treated in clinical practice, the low inflammatory profiles of these patients may have obscured treatment effect differences. Reassuringly, the majority of effectiveness outcomes in the RRMS subgroup were also comparable. Finally, this study included data from 2 large academic MS centers, which may lessen generalizability to smaller community-based practices with different methods of treatment counseling.

These 2-center results confirm previous single-center 24-month studies demonstrating increased odds of DMF discontinuation compared to FTY, largely driven by intolerability. Reassuringly, our data substantiate DMT persistence in longer-term disease management for both DMF and FTY. Similar to respective phase 3 trial data and other observational studies, our results further confirm comparable clinical and radiographic effectiveness profiles of these DMTs in clinical practice.
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